Organoid research in diabetes and cardiovascular diseases: bibliometric mapping of knowledge evolution and emerging frontiers in organ-on-a-chip systems, bioprinting, artificial intelligence, and multi-omics
This bibliometric analysis of 802 publications from 2016 to 2025 maps the rapid evolution of organoid and organ-on-a-chip research in diabetes and cardiovascular diseases, highlighting a paradigm shift toward high-fidelity disease modeling driven by the integration of bioprinting, single-cell omics, and artificial intelligence.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine you are trying to build a tiny, working city inside a petri dish to understand how a real city breaks down when a storm hits. For decades, scientists tried to do this by laying out flat, two-dimensional tiles (cells) on a glass slide. But real cities aren't flat; they have skyscrapers, underground tunnels, and complex neighborhoods that interact in 3D. To fix this, scientists started building "organoids"—tiny, self-assembling blobs of cells that grow into miniature, 3D versions of human organs like hearts and pancreases. Think of them as living, breathing LEGO sets that mimic the real thing much better than flat tiles ever could.
However, diabetes and heart disease are like a double-storm; they often hit the body at the same time, messing up both the sugar-processing factory (the pancreas) and the pump (the heart). Studying them separately is like trying to fix a car engine while ignoring the fuel line. Scientists are now racing to combine these tiny organ models with super-advanced tools like 3D bioprinters (which print living tissue layer by layer), "organ-on-a-chip" systems (miniature labs on a plastic card that mimic blood flow), and artificial intelligence (AI) to read the data. The big question is: How fast is this new way of doing science growing, and where is it heading?
This paper acts like a giant mapmaker for that race. Instead of building a new organoid itself, the authors, led by Chao Fu and Chunlin Li, used a method called "bibliometrics" to scan 802 scientific papers published between 2016 and 2025. They treated these papers like footprints in the snow, tracing where scientists have been, who is working together, and what tools they are using. They found that the field is exploding, growing by nearly 20% every year, with a massive jump in activity starting in 2021. The United States and China are the two biggest players, leading a global team that is shifting its focus.
The map reveals a clear change in direction. In the early days, scientists were mostly focused on just "how do we build these tiny organs?" But the paper suggests the field has matured. Now, the focus is shifting from simply constructing the models to using them as high-fidelity simulators to understand exactly how diabetes damages the heart and to test new drugs. The most exciting "frontier" areas the authors spotted are the integration of bioprinting to make these models more precise, single-cell sequencing to read the genetic code of individual cells inside the blobs, and AI to help make sense of the massive amounts of data these models produce.
The authors suggest that we are moving away from isolated experiments toward a "platform-based" future. Imagine a factory where bioprinters build the organ, chips provide the blood flow, and AI acts as the quality control manager, all working together to create a perfect testbed for new medicines. While the paper notes that this is a rapidly expanding and promising field, it also reminds us that we are still in the development phase. The tools are getting better, the collaboration is getting stronger, and the goal is clear: to create models so realistic that they can help us prevent and treat the complex dance between diabetes and heart disease before they ever reach a human patient.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.